ArticleMycopathologia2022
Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples.
Article in Mycopathologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Fluconazole Disk Diffusion on CHROMagar Candida Plus for Differentiation BetweenJournal of fungi (Basel, Switzerland) · 2026Article
- Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options.Archives of microbiology · 2026Review
- Caspofungin Reshapes the Extracellular Vesicles Metabolome ofJournal of fungi (Basel, Switzerland) · 2026Article
- Identification of rare Candida species isolated from various clinical specimens: Comparison of different methods.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Expansion of the Candidozyma haemuli Species Complex - The Novel Species Candidozyma molenica, Isolated from Clinical and Environmental Sources.Mycopathologia · 2025Article
- Diagnostic Approaches forMicroorganisms · 2025Review
- Pathogenicity Evaluation on Fluconazole-Resistant Candida auris Clade V in Murine Model.Mycopathologia · 2025Article
- Keep the Hospital Clean: Diagnostic Performance of Ten Different Molecular and Culture-Based Methods to Detect Candidozyma (Candida) auris.Mycopathologia · 2025Article
- Review
- Diversity and Antifungal Susceptibilities of Yeasts from Mangroves in Hong Kong, China-A One Health Aspect.Journal of fungi (Basel, Switzerland) · 2024Article
- Performance of common primary and chromogenic culture media for MALDI-TOF MS identification of clinically relevant yeasts.Microbiology spectrum · 2024Article
- A simple and sensitive test forJournal of clinical microbiology · 2024Article
- Review
- Does Candida auris colonize the oral cavity? A retrospective institutional experience.Oral diseases · 2024Article
- Review
- Evaluation of CHROMagarMicrobiology spectrum · 2024Article
- Synthesis of new imidazole-based ionic liquids with antifungal activity againstIranian journal of microbiology · 2023Article
- Identification and antifungal resistance profiling ofAnnals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Candida auris is a nosocomial fungal pathogen of prime importance due to its global emergence and rapid spread in healthcare facilities worldwide. One important concern is that routine, conventional methods fail to identify C. auris. While molecular and protein-based assays accurately detect/identify C. auris, these methods are time-consuming, expensive, and require expertise. Therefore, the objective of the present study was to assess the potential use of a novel chromogenic medium, CHROMagar™ Candida Plus, as an economical alternative to expensive and laborious diagnostic tests. We compared CHROMagar™ Candida Plus with the standard enrichment (salt Sabouraud Dulcitol broth) medium to test the recovery efficiency of C. auris from surveillance samples. We also tested CHROMagar™ Candida Plus for its ability to distinguish C. auris from other yeast species. One hundred surveillance samples were cultured on CHROMagar™ Candida Plus and Dulcitol broth and incubated at 37 °C and 40 °C, respectively. Additionally, 32 Candida and yeast species were cultured on CHROMagar™ Candida Plus at 37 °C for three days to rule out any close resemblance to C. auris. Of 100 surveillance samples tested, 69 yielded presumptive positive C. auris exhibiting creamy pink colonies with a blue halo on CHROMagar™ Candida Plus within three days of incubation, and MALDI-TOF MS confirmed all by day 4. On the other hand, 69 of 100 surveillance samples yielded turbidity in Dulcitol broth by days 3-14 with final MALDI identification by days 5 to 17. Both media failed to identify one sample each, resulting in assay sensitivity and specificity of 99% and 97%, respectively. Of Candida and yeast species tested, 75-80% of C. metapsilosis and C. orthospilosis were misidentified as C. auris. However, previous studies indicated that these species are rarely detected in surveillance screening of C. auris. Naganishia diffluens also resembled C. auris, although it required different temperature growth (30 °C). In conclusion, CHROMagar™ Candida Plus provides rapid presumptive identification of C. auris. It would be another valuable tool in surveillance efforts to control the spread of C. auris in healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.